Compare NBIX & AMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | AMCR |
|---|---|---|
| Founded | 1992 | 1926 |
| Country | United States | Switzerland |
| Employees | N/A | 50000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 20.7B |
| IPO Year | 1996 | 2020 |
| Metric | NBIX | AMCR |
|---|---|---|
| Price | $167.43 | $43.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 13 |
| Target Price | ★ $208.11 | $50.98 |
| AVG Volume (30 Days) | 1.3M | ★ 3.7M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 6.03% |
| EPS Growth | 41.95 | ★ 643.75 |
| EPS | ★ 5.26 | 0.52 |
| Revenue | $161,626,000.00 | ★ $13,640,000,000.00 |
| Revenue This Year | $39.52 | $2.20 |
| Revenue Next Year | $14.81 | $2.43 |
| P/E Ratio | ★ $32.28 | $84.51 |
| Revenue Growth | ★ 977.51 | 9.40 |
| 52 Week Low | $122.14 | $8.09 |
| 52 Week High | $186.12 | $50.94 |
| Indicator | NBIX | AMCR |
|---|---|---|
| Relative Strength Index (RSI) | 66.05 | 43.35 |
| Support Level | $152.67 | $41.19 |
| Resistance Level | $169.57 | $45.22 |
| Average True Range (ATR) | 5.47 | 1.15 |
| MACD | 2.07 | -0.43 |
| Stochastic Oscillator | 80.70 | 1.68 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. Since the Berry acquisition in 2025, about 60% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which includes beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.